PT - JOURNAL ARTICLE AU - Wang, Changjun AU - Lin, Yan AU - Xu, Ying AU - Mao, Feng AU - Guan, Jinghong AU - Wang, Xuejing AU - Zhang, Yanna AU - Zhang, Xiaohui AU - Shen, Songjie AU - Zhong, Ying AU - Pan, Bo AU - Peng, Li AU - Huang, Xin AU - Cao, Xi AU - Yao, Ru AU - Zhou, Xintong AU - He, Zecheng AU - Liu, Yuhan AU - Lang, Jie AU - Li, Chenggang AU - Zhou, Yidong AU - Sun, Qiang TI - Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial AID - 10.1101/2024.08.19.24311958 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.19.24311958 4099 - http://medrxiv.org/content/early/2024/08/20/2024.08.19.24311958.short 4100 - http://medrxiv.org/content/early/2024/08/20/2024.08.19.24311958.full AB - Background Pyrotinib, a pan-HER tyrosine kinase inhibitor, demonstrates efficacy in the treatment of HER2-positive breast cancer. However, the frequent occurrence of treatment-emergent diarrhea necessitating discontinuation, impacts patient outcomes.Methods In this multicenter, open-label, phase II PHAEDRA study enrolling early stage HER2-positive patients for postoperative treatment with nab-paclitaxel and pyrotinib, 120 patients were included for a sub-study and randomly divided into two groups to receive 21 days and 42 days of loperamide for primary prophylaxis of diarrhea, followed by as-needed usage. The primary outcome was the incidence of grade ≥3 diarrhea.Results Fifty-eight patients in the 21-day group and 59 patients in the 42-day group received at least one dose of pyrotinib. With a median follow-up of 12.1 months, all patients experienced diarrhea of any grade, with grade ≥3 events in 39.7% of the 21-day group and 42.4% of the 42-day group (relative risk: 0.94; 95% confidence interval: 0.61-1.45). The most common treatment-emergent adverse events, other than diarrhea, were hypoesthesia, vomiting, nausea, and rash, mostly grade 1-2, except for one case of grade ≥3 decreased neutrophil count in each group.Conclusion No significant differences were observed between 21-day and 42-day loperamide durations in preventing grade ≥3 diarrhea. Considering the economic cost and patient compliance, 21-day loperamide prophylaxis might represent a more pragmatic and appropriate approach for clinical application.Trial registration ClinicalTrials.gov, NCT04659499Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04659499Funding StatementThe study drugs pyrotinib and nab-paclitaxel were provided by Jiangsu Hengrui Pharmaceuticals Co., Ltd. This study was funded by the National High-Level Hospital Clinical Research Funding (No. 2022-PUMCH-B-038 and No. 2022-PUMCH-C-066) and TSC China Allicace (#LAM001-202205).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional ethics committee at the Peking Union Medical College Hospital (approval number: HS-2617) with informed consent obtained from all patients in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe raw clinical data were protected and not available owing to data privacy laws. The de-identified datasets supporting the findings of this study are available for academic purposes on request from the corresponding author, Qiang Sun (sunqiangpumch{at}sina.com), for five years, with the approval of the Institutional Ethical Committees.